Last reviewed · How we verify
NCT05939908
Assessment of Hand Grip Strength Using Jamar Dynamometer
trial testing Using Jamar Dynamometer for Grip Strength. in Type2diabetes in 5,000 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Diabetes Foundation, India |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 5,000 |
| Start date | 1 July 2023 |
| Primary completion | 31 December 2024 |
| Estimated completion | 30 January 2025 |
| Sites | 1 location across India |
Drugs / interventions tested
- Using Jamar Dynamometer for Grip Strength.
Conditions studied
- Type2diabetes — all drugs for Type2diabetes →
Sponsor
Diabetes Foundation, India
Who can join
Adults 20 to 60, any sex, with Type2diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hand grip strength will be measured for all the type 2 diabetic patients. Measurement of maximal grip strength will be performed using Jamar dynamometers, which estimate the muscle strength primarily generated by the flexor muscles of the hand and the forearm. The Jamar displays grip force in both pounds and kilograms, with a maximum of 200 lb (90 kg). It has a peak-hold needle that automatically retains the highest reading until reset. The Jamar test is isometric, with no perceptible motion of the handle, regardless of the grip strength applied. The participants will be encouraged to produce their maximal grip strength. Three trials will be recorded, consisting of a 2-4-second maximal contraction, with a 30-second rest period between each trial. The average of the three readings will be taken.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05939908
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type2diabetes
Currently open trials in the same condition.
- NCT06345196 — Motivational Interviewing Applied to Individuals With Diabetes · NA · recruiting
- NCT06322212 — Type 2 Diabetes and Blood Brain Barrier Improvement · EARLY_PHASE1 · recruiting
- NCT06575478 — Evaluation of Fuling Yunhua Granules and Dihuang Baoyuan Granules in Drug Naive Type 2 Diabetes Patients · Phase 2 · recruiting
- NCT06469437 — The Impact of Geriatric Assessment on the Treatment Plan of Elderly Patients With T2DM · NA · recruiting
- NCT06875193 — DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes · Phase 4 · recruiting
Other Diabetes Foundation, India trials
Trials by the same sponsor.
- NCT07205705 — Impact of Partially Replacing Wheat With Millets or Bengal Gram Flour in Rotis on Glycemia and Prediabetes Reversal · NA · not yet recruiting
- NCT06454773 — To Evaluate the Impact of Consumption of Bioactive Compounds Extracted From Hemp Hull and Black Pepper on Fasting Blood · Phase 3 · recruiting
- NCT06386939 — Comparison of Micro- and Macrovascular Disease(s) in People With T2D, Who Have Moderate to Severe Acanthosis Nigricans v · recruiting
- NCT06386952 — To Compare People With T2DM Who Have Double Hump Versus Who do Not Have Double Hump · recruiting
- NCT05925946 — Effect of Low-Calorie Diet and Lifestyle Intervention on Reversal of T2DM · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05939908 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Diabetes Foundation, India
- Last refreshed: 11 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05939908.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing